Abstract:Glycosylation of the immunoglobulin G (IgG)-Fc tail is required for binding to Fc-gamma receptors (FcγRs) and complement-component C1q. A variety of IgG1-glycoforms is detected in human sera. Several groups have found global or antigen-specific skewing of IgG glycosylation, for example in autoimmune diseases, viral infections, and alloimmune reactions. The IgG glycoprofiles seem to correlate with disease outcome. Additionally, IgG-glycan composition contributes significantly to Ig-based therapies, as for example IVIg in autoimmune diseases and therapeutic antibodies for cancer treatment. The effect of the different glycan modifications, especially of fucosylation, has been studied before. However, the contribution of the 20 individual IgG glycoforms, in which the combined effect of all 4 modifications, to the IgG function has never been investigated. Here, we combined six glyco-engineering methods to generate all 20 major human IgG1-glycoforms and screened their functional capacity for FcγR and complement activity. Bisection had no effect on FcγR or C1q-binding, and sialylation had no- or little effect on FcγR binding. We confirmed that hypo-fucosylation of IgG1 increased binding to FcγRIIIa and FcγRIIIb by ~17-fold, but in addition we showed that this effect could be further increased to ~40-fold for FcγRIIIa upon simultaneous hypo-fucosylation and hyper-galactosylation, resulting in enhanced NK cell-mediated antibody-dependent cellular cytotoxicity. Moreover, elevated galactosylation and sialylation significantly increased (independent of fucosylation) C1q-binding, downstream complement deposition, and cytotoxicity. In conclusion, fucosylation and galactosylation are primary mediators of functional changes in IgG for FcγR- and complement-mediated effector functions, respectively, with galactose having an auxiliary role for FcγRIII-mediated functions. This knowledge could be used not only for glycan profiling of clinically important (antigen-specific) IgG but also to optimize therapeutic antibody applications.

Glycan-independent Binding and Internalization of Human IgM to FCMR, Its Cognate Cellular Receptor

Molecular Recognition of Fc-Specific Ligands Binding Onto the Consensus Binding Site of Igg: Insights from Molecular Simulation

Effects of Anchor Structure and Glycosylation of Fcγ Receptor III on Ligand Binding Affinity.

Structural Insights into Immunoglobulin M

Molecular mechanism of IgM perception by IgM-specific receptor FcμR

Localization of the binding site for the monocyte immunoglobulin (Ig) A-Fc receptor (CD89) to the domain boundary between Calpha2 and Calpha3 in human IgA1

Immunoglobulin M perception by FcμR

Influence of glycan modification on IgG1 biochemical and biophysical properties

Monomeric IgG1 Fc Molecules Displaying Unique Fc Receptor Interactions That Are Exploitable to Treat Inflammation-Mediated Diseases.

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities

Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs

Site-Specific Glycosylation Analysis of Human and Murine Fcγ Receptor II Family Members Reveals Variant-Specific N-Glycosylation

Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors

NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation.

Site-Specific Glycosylation Analysis of Murine and Human Fcγ Receptors Reveals High Heterogeneity at Conserved N -Glycosylation Site

Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1

Binding Site on Human Immunoglobulin G for the Affinity Ligand HWRGWV.

The Ligands for Human IgG and Their Effector Functions

Regulation of Humoral Immune Responses and B Cell Tolerance by the IgM Fc Receptor (FcμR).

IgG N-glycans

Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies